BFM
ABCL icon

Boothbay Fund Management’s AbCellera Biologics ABCL Stock Holding History

Boothbay Fund Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,703
Closed -$46K – 1359
2024
Q4 		$46K Buy
+15,703
New +$43.7K ﹤0.01% 1364
2022
Q3 		– Sell
-10,793
Closed -$115K – 2195
2022
Q2 		$115K Buy
+10,793
New +$91.4K ﹤0.01% 1949

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boothbay Fund Management's ABCL Position: Q1 2025 in Review

Boothbay Fund Management sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 15,703 shares — an estimated $46K sold.

Boothbay Fund Management first reported a position in ABCL in Q2 2022 and held it in 2 quarters. The position peaked at $115K in Q2 2022. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • Boothbay Fund Management reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 15,703 AbCellera Biologics shares in Q1 2025, an estimated $46K.
  • Boothbay Fund Management first reported a position in AbCellera Biologics in Q2 2022 and held it in 2 quarters.
  • Boothbay Fund Management's AbCellera Biologics position peaked at $115K in Q2 2022.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.